Mach7 Technologies (M7T) investor relations material

Executive summary

• Undertook a comprehensive organizational and commercial reset, including leadership changes, cost discipline, and a sharpened product and go-to-market strategy, with new sales leadership and operational efficiencies.

• Launched the modular Flamingo architecture, securing the first customer in December 2025 and targeting customer-specific imaging needs and new revenue streams.

• Achieved CE mark for eUnity under EU Medical Device Regulation, supporting expansion in Europe and the Middle East.

• Enhanced customer engagement through the Flight Crew model and improved KLAS scores.

• Reported a net loss after tax of $5.75 million for the half-year ended 31 December 2025, compared to a $1.87 million loss in the prior period.

Financial highlights

• Revenue for H1 FY26 was AUD 13.7 million, down 23% year-over-year due to lower capital license and professional services sales.

• Recurring revenue was AUD 11.6 million (85% of total), down 8% year-over-year.

• Gross margin remained strong at 92% (down from 94% year-over-year), reflecting platform scalability.

• Operating expenses decreased by 6% to AUD 14.8 million as cost initiatives took effect.

• Adjusted EBITDA was -AUD 2.3 million (prior period: AUD 0.8 million); NPAT was -AUD 5.7 million (prior period: -AUD 1.9 million).

Outlook and guidance

• Expecting flat revenue for FY26, with growth anticipated in FY27 as commercial momentum builds and Flamingo adoption increases.

• Continued disciplined investment in sales, partnerships, product development, and platform scalability.

• Enhanced marketing and sales initiatives, including a refreshed brand and digital presence, are underway.